Nereus Pharmaceuticals Rounds Up $20M More

San Diego-based Nereus Pharmaceuticals, a firm developing drugs for the treatment of lung cancer, said Tuesday that it has raised another $20M in funding and commitments from its venture backers. The new funding round was led by HBM Bioventures, and also included Alta Partners, Forward Ventures, Gimv, Advent International, Pacific Venture Group, Roche Venture Fund, and Astellas Venture Management. Nereus said the funding came as a result of the completion of enrollment in a randomized, Phase 2 ADVANCE study evaluating its plinabulin (NPI-2358) compound for treating non-small cell lung cancer in patients who have failed treatment with chemotherapy. More information »